Over the past decade methods for delivering genes into mammalian cells
aimed at subsequent expression of the transferred sequences from the
host cell have been developped. Potential therapeutic applications hav
e been envisaged and have raised great interest. Though procedures bas
ed on gene targeting will not enter clinical protocols prior to the so
lving of fundamental issues, procedures based on gene addition are cur
rently underway. The expected benefit of genetic modification of somat
ic cells needs to be carefully assessed and confronted to its potentia
l risks. Whatever the technological strategy, non-propagation and non-
transmission of the gene transfer delivery system is mandatory. Precli
nical studies covering a large range of pathologies are currently unde
rway; primarily aimed at demonstrating rather the technological feasib
ility of various approaches than true therapeutic efficacy. Technologi
cal improvements and the solving of basic issues dealing with both the
regulation of gene expression and the biology of cell transplantation
are still required in order for gene therapy to enter a phase of clin
ical efficacy. Pluridisciplinarity only will allow for fruitful exchan
ges between investigators in the basic sciences and therapists. This h
as been the basis for creating a European Working group on human Gene
Transfer and therapy (EWGT). Whatever the interest raised by gene ther
apy and its innovatory potential, the relevance of this approach shoul
d carefully be considered 1st) in terms of economical constraints and
ethics; 2nd) in the context of an overall therapeutic strategy, in par
ticular in the case of acquired disease like cancer, and confronted to
alternative treatments such as targeted drugs.